| Price | 27.825 on 17-12-2025 at 13:00:03 |
|---|---|
| Change | -0.175 -0.63% |
| Buy | 29.20 |
| Sell | 26.45 |
| Last Trade: | Sell 67.00 at 27.70 |
| Day's Volume: | 0 |
| Last Close: | 28.00 |
| Open: | 27.775 |
| ISIN: | SE0015244520 |
| Day's Range | 26.40 - 27.825 |
| 52wk Range: | 21.95 - 42.775 |
| Market Capitalisation: | - |
| VWAP: | 0.00 |
| Shares in Issue: | 65.80m |
Bioinvent Inter (0H22) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 67 | 27.70 | SI Trade |
13:41:20 - 16-Dec-25 |
| Sell* | 67 | 27.70 | SI Trade |
13:41:20 - 16-Dec-25 |
| Sell* | 89 | 27.75 | SI Trade |
13:13:55 - 16-Dec-25 |
| Sell* | 95 | 27.85 | SI Trade |
10:59:35 - 16-Dec-25 |
| Sell* | 95 | 27.85 | SI Trade |
10:59:35 - 16-Dec-25 |
| Sell* | 95 | 27.85 | SI Trade |
10:18:11 - 16-Dec-25 |
| Sell* | 95 | 27.85 | SI Trade |
10:18:11 - 16-Dec-25 |
| Sell* | 86 | 27.95 | SI Trade |
09:27:52 - 16-Dec-25 |
| Sell* | 86 | 27.95 | SI Trade |
09:27:52 - 16-Dec-25 |
| Sell* | 418 | 28.50 | SI Trade |
08:54:59 - 12-Dec-25 |
Bioinvent Inter (0H22) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |
